← All trials
NCT06065176
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 22, 2023
- Primary completion
- Jul 30, 2024
- Completion date
- Jul 30, 2024
- First posted
- Oct 3, 2023
- Last posted
- Nov 28, 2023
- Enrollment
- 1500
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of UtahLead sponsor
- NovavaxCollaborator
- WestatCollaborator
- University of UtahOverall official - principal investigator
- University of UtahSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.